SGA
ACAD icon

Sector Gamma AS’s Acadia Pharmaceuticals ACAD Stock Holding History

Sector Gamma AS’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-188,111
Closed -$5.89M – 30
2023
Q4 		$5.89M Buy
188,111
+8,326
+5% +$199K 1.43% 24
2023
Q3 		$3.75M Sell
179,785
-20,911
-10% -$568K 0.96% 24
2023
Q2 		$4.81M Sell
200,696
-32,022
-14% -$712K 1.08% 24
2023
Q1 		$4.38M Buy
232,718
+46,883
+25% +$893K 1.06% 26
2022
Q4 		$2.96M Buy
+185,835
New +$2.9M 0.68% 28

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Sector Gamma AS's ACAD Position: Q1 2024 in Review

Sector Gamma AS sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 188,111 shares — an estimated $5.89M sold.

Sector Gamma AS first reported a position in ACAD in Q4 2022 and held it in 5 quarters. The position peaked at $5.89M in Q4 2023. 267 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

  • Sector Gamma AS reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Sector Gamma AS sold 188,111 Acadia Pharmaceuticals shares in Q1 2024, an estimated $5.89M.
  • Sector Gamma AS first reported a position in Acadia Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • Sector Gamma AS's Acadia Pharmaceuticals position peaked at $5.89M in Q4 2023.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on Sector Gamma AS's 13F filing for Q1 2024, filed 8 May 2024.